Catalyst Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Catalyst Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,210	Closed	-$161K	–	351
2022 Q1	$161K	Hold	2,210	–	–	0.01%	250
2021 Q4	$138K	Hold	2,210	–	–	0.01%	235
2021 Q3	$131K	Sell	2,210 -14,478	-87%	-$953K	0.01%	250
2021 Q2	$1.11M	Sell	16,688 -5,790	-26%	-$378K	0.06%	164
2021 Q1	$1.42M	Hold	22,478	–	–	0.08%	147
2020 Q4	$1.39M	Hold	22,478	–	–	0.08%	137
2020 Q3	$1.35M	Hold	22,478	–	–	0.08%	132
2020 Q2	$1.32M	Sell	22,478 -4,317	-16%	-$258K	0.07%	130
2020 Q1	$1.49M	Buy	+26,795	New	+$1.64M	0.07%	97

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Catalyst Capital Advisors's BMY Position: Q2 2022 in Review

Catalyst Capital Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2022, closing a stake of 2,210 shares — an estimated $161K sold.

Catalyst Capital Advisors first reported a position in BMY in Q1 2020 and held it in 9 quarters. The position peaked at $1.49M in Q1 2020. 2,537 funds tracked by Wall St. Rank hold BMY as of Q2 2022.

Catalyst Capital Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2022 after selling out during the quarter.
Catalyst Capital Advisors sold 2,210 Bristol-Myers Squibb shares in Q2 2022, an estimated $161K.
Catalyst Capital Advisors first reported a position in Bristol-Myers Squibb in Q1 2020 and held it in 9 quarters.
Catalyst Capital Advisors's Bristol-Myers Squibb position peaked at $1.49M in Q1 2020.
2,537 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2022.

Based on Catalyst Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.